Viridian Therapeutics shares fall over 30% after trial data disappoints [Yahoo! Finance]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
Shares of Viridian Therapeutics (NASDAQ:VRDN) fell more than 30% Monday morning following the release of topline results from the company's REVEAL-1 trial in active thyroid eye disease (TED). The study, which tested the subcutaneous formulation of elegrobart, met its primary endpoint, signaling that the drug could gain approval. However, efficacy fell short of investor expectations, fueling debate over its commercial potential. According to Jefferies, the pbo-adjusted proptosis response was 36% for the Q4W dosing schedule and 45% for Q8W, below expectations of more than 50% and trailing performance seen with intravenous competitors such as veli (65%) and Tepezza (51%-73%). Complete diplopia resolution was also mixed, with Q4W at 35% and Q8W at 12%, compared with 42% for IV veli and 28% for Tepezza. “Elegrobart appears to be a real drug that could expand the TED market with subcutaneous dosing, particularly for infusion-averse patients,” Jefferies wrote. “But debate is likely on
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics (VRDN) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics (VRDN) had its price target lowered by Truist Financial Corporation from $36.00 to $33.00. They now have a "buy" rating on the stock.MarketBeat
- Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 20% [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics price target lowered to $36 from $40 at Truist [Yahoo! Finance]Yahoo! Finance
VRDN
Earnings
- 2/26/26 - Miss
VRDN
Sec Filings
- 4/17/26 - Form ARS
- 4/17/26 - Form DEFA14A
- 4/17/26 - Form DEF
- VRDN's page on the SEC website